SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sharon Bio-Medicine surges on filing ANDA for Memantine Hydrochloride Tablets

13 Feb 2012 Evaluate

Sharon Bio-Medicine is currently trading at Rs. 341.00, up by 5.30 points or 1.58% from its previous closing of Rs. 335.70 on the BSE.

The scrip opened at Rs. 336.00 and has touched a high and low of Rs. 341.00 and Rs. 335.00 respectively. So far 59022 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 341.00 on 13-Feb-2012 and a 52 week low of Rs. 131.05 on 17-Feb-2011.

Last one week high and low of the scrip stood at Rs. 341.00 and Rs. 322.10 respectively. The current market cap of the company is Rs. 359.99 crore.

The promoters holding in the company stood at 60.74% while Institutions and Non-Institutions held 0.23% and 39.03% respectively.

Sharon Bio-Medicine has filed its ANDA for Memantine Hydrochloride Tablets, 5mg and 10mg tablets from its drug product manufacturing facility at Silaqui, Dehradoon, Uttarakhand. The company has also filed its own DMF for the drug substance which will be used in manufacturing of the drug namely Memantine Hydrochloride from its drug substance manufacturing facility at Taloja, Navi Mumbai.

Memantine Hydrochloride Tablets are the generic version of the Namenda Tablets manufactured by USA based- Forest Laboratories, used for the treatment of moderate to severe dementia of the Alzheimer’s type.

With this integrated filing of the drug master file and the ANDA, Sharon expects the approval of both of its manufacturing facility by September 2012, post inspection of the manufacturing facility by USFDA.

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×